Bienville Capital Management LLC Continues to Hold Holdings in Pfizer Inc. (PFE)

Bienville Capital Management LLC maintained its stake in shares of Pfizer Inc. (NYSE:PFE) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,148 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Bienville Capital Management LLC’s holdings in Pfizer were worth $240,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Northstar Group Inc. increased its stake in shares of Pfizer by 0.4% during the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 35 shares during the period. River Wealth Advisors LLC increased its stake in shares of Pfizer by 0.3% during the second quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock valued at $531,000 after buying an additional 55 shares during the period. Meridian Wealth Management LLC increased its stake in shares of Pfizer by 0.5% during the second quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock valued at $402,000 after buying an additional 57 shares during the period. Stone House Investment Management LLC increased its stake in shares of Pfizer by 0.9% during the first quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock valued at $245,000 after buying an additional 66 shares during the period. Finally, Autus Asset Management LLC increased its stake in shares of Pfizer by 1.2% during the second quarter. Autus Asset Management LLC now owns 6,681 shares of the biopharmaceutical company’s stock valued at $225,000 after buying an additional 78 shares during the period. Hedge funds and other institutional investors own 69.89% of the company’s stock.

Several equities analysts have recently issued reports on PFE shares. BMO Capital Markets set a $37.00 target price on Pfizer and gave the company a “buy” rating in a research note on Tuesday, October 10th. ValuEngine raised Pfizer from a “hold” rating to a “buy” rating in a research note on Friday, October 6th. Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Morgan Stanley raised Pfizer from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $35.00 to $39.00 in a research note on Wednesday, September 20th. Finally, Deutsche Bank set a $38.00 target price on Pfizer and gave the company a “buy” rating in a research note on Wednesday, October 11th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $38.77.

Pfizer Inc. (NYSE:PFE) traded down $0.07 during trading on Thursday, reaching $35.56. The company’s stock had a trading volume of 17,379,200 shares, compared to its average volume of 19,978,311. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. Pfizer Inc. has a twelve month low of $30.51 and a twelve month high of $36.78. The company has a market capitalization of $212,380.00, a P/E ratio of 14.25, a price-to-earnings-growth ratio of 2.51 and a beta of 1.01.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. During the same period in the previous year, the company posted $0.61 earnings per share. The company’s revenue for the quarter was up .9% compared to the same quarter last year. equities analysts expect that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, December 1st. Shareholders of record on Friday, November 10th were issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 3.60%. The ex-dividend date was Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is 79.01%.

In other news, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the transaction, the insider now directly owns 145,649 shares of the company’s stock, valued at $5,097,715. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $35.65, for a total value of $262,027.50. Following the transaction, the executive vice president now directly owns 117,432 shares in the company, valued at $4,186,450.80. The disclosure for this sale can be found here. Insiders sold 60,280 shares of company stock worth $2,118,988 over the last three months. Corporate insiders own 0.06% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.com-unik.info/2017/12/07/bienville-capital-management-llc-continues-to-hold-holdings-in-pfizer-inc-pfe.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit